Fig. 8

The synergistic antitumor effects of targeting ACTN1 and cisplatin in a PDX model. A-C Evaluation of tumor growth in PDX cells treated with a combination of ACTN1 inhibition and cisplatin, compared with cells subjected to either ACTN1 inhibition or cisplatin alone. D-F Assessment of tumor-initiating potential in cancer cells extracted from PDX tumors across the different treatment groups. G Schematic representation of the proposed molecular mechanisms, illustrating the dual role of ACTN1 in promoting tumorigenesis and conferring drug resistance in HNSCC. **P < 0.01, ***P < 0.001